New York, New York-- (Newsfile Corp. - September 22, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Investors have also been growing concerned about its prospects, especially if weight loss drugs can lead to a reduction in diabetes cases in the long run. Down more than 40% this year, DexCom's ...

NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the ...

When the market learned the truth about DexCom, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in ...

Higgins cites the growing use cases for GLP-1s, particularly in the treatment of pre-diabetic patients, as a forceful headwind to DexCom. Its glucose monitoring devices are only designed for a ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...